Publications by authors named "Adrianna L De La Torre"

Cholesterol homeostasis is pivotal for cellular function. Acyl-coenzyme A:cholesterol acyltransferase 1 (ACAT1), also abbreviated as SOAT1, is an enzyme responsible for catalyzing the storage of excess cholesterol to cholesteryl esters. ACAT1 is an emerging target to treat diverse diseases including atherosclerosis, cancer, and neurodegenerative diseases.

View Article and Find Full Text PDF

Cholesterol is essential for cellular function and is stored as cholesteryl esters (CEs). CEs biosynthesis is catalyzed by the enzymes acyl-CoA:cholesterol acyltransferase 1 and 2 (ACAT1 and ACAT2), with ACAT1 being the primary isoenzyme in most cells in humans. In Alzheimer's Disease, CEs accumulate in vulnerable brain regions.

View Article and Find Full Text PDF

Cholesterol serves as an essential lipid molecule in various membrane organelles of mammalian cells. The metabolites of cholesterol also play important functions. Acyl-coenzyme A: cholesterol acyltransferase 1 (ACAT1), also named as sterol -acyltransferase 1, is a membrane-bound enzyme residing at the endoplasmic reticulum (ER).

View Article and Find Full Text PDF
Article Synopsis
  • ACAT inhibitors, which may help treat diseases like Alzheimer's and cancer, have been difficult to deliver effectively; this study focuses on encapsulating them in nanoparticles.
  • A new method using F12511 as a model involves mixing it with specific phospholipids in ethanol to create stable stealth liposomes, achieving successful encapsulation and high stability.
  • The resulting nanoparticles exhibit strong ACAT inhibition with minimal toxicity and may offer a cost-effective way to enhance drug delivery and potentially combine with other therapies.
View Article and Find Full Text PDF

Because PEGylated molecules exhibit different physicochemical properties from those of the parent molecules, PEGylated interferonβ-1a (pegIFNβ-1a) may be able to be used with retained bioactivity in Multiple Sclerosis (MS) patients who have previously developed neutralizing antibodies (NABs) to recombinant interferonβ (rIFNβ). Hence, the objective of the present study was to test whether pegIFNβ-1a is less antigenic for NABs in vitro than rIFNβ. Two in vitro assays were used to quantitate NABs in 115 sera obtained from MS patients included in the INSIGHT study: the cytopathic effect (CPE) assay, and the MxA protein induction assay.

View Article and Find Full Text PDF